Published in J Virol on April 03, 2013
Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer. Front Oncol (2014) 0.85
Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors. J Virol (2015) 0.84
Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells. J Virol (2014) 0.79
Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells. PLoS One (2014) 0.78
Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector. Virology (2014) 0.77
Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis. J Virol (2015) 0.75
Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition. Biomark Cancer (2016) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 4.37
The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol (1996) 3.89
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 2.72
Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2010) 2.56
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol (2002) 2.44
Gene expression of vesicular stomatitis virus genome RNA. Virology (1992) 2.37
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell (2011) 2.17
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol (2003) 2.10
VSV-tumor selective replication and protein translation. Oncogene (2005) 1.88
Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life (2000) 1.81
Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem (1997) 1.76
Inhibition of vesicular stomatitis virus mRNA synthesis by human MxA protein. J Virol (1991) 1.74
Vesicular stomatitis virus glycoprotein containing the entire green fluorescent protein on its cytoplasmic domain is incorporated efficiently into virus particles. Virology (2001) 1.68
Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology (2006) 1.66
Transcriptional activation of alpha/beta interferon genes: interference by nonsegmented negative-strand RNA viruses. J Virol (2005) 1.64
Interferon, Mx, and viral countermeasures. Cytokine Growth Factor Rev (2007) 1.54
Current management and novel agents for malignant melanoma. J Hematol Oncol (2012) 1.53
Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res (2003) 1.50
Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res (2010) 1.50
Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie (2007) 1.48
Ipilimumab in the treatment of melanoma. Expert Opin Biol Ther (2012) 1.47
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther (2011) 1.45
Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol (2006) 1.42
Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control (2009) 1.41
Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res (2011) 1.38
Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst (2006) 1.36
Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol (2005) 1.34
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther (2009) 1.30
Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol (2005) 1.28
Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res (2010) 1.27
Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J Virol (2009) 1.25
Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J Virol (2006) 1.24
Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci (2008) 1.21
Measles virus causes immunogenic cell death in human melanoma. Gene Ther (2011) 1.19
Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol Methods (2010) 1.18
Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet (2001) 1.17
VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol Ther (2010) 1.15
Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res (2002) 1.14
Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res (2012) 1.10
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol (2012) 1.08
Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther (2009) 1.04
Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol (2011) 1.04
Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alpha. J Virol (2006) 1.04
Adjuvant therapy for melanoma. Cancer J (2012) 1.01
The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev (2004) 1.01
Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants. Int J Cancer (2004) 0.98
Rab33A: characterization, expression, and suppression by epigenetic modification. J Invest Dermatol (2006) 0.98
Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer Immunol Immunother (2011) 0.95
Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther (2011) 0.94
Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery (2012) 0.89
Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma. Exp Dermatol (2008) 0.88
Treatment of melanoma brain metastases: a new paradigm. Cancer J (2012) 0.86
Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity. J Virol (2012) 0.85
Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis. J Virol (2012) 0.84
Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. BMC Cancer (2011) 0.84
Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol (2011) 0.84
Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain. J Virol (2009) 0.81
Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18. Virol J (2011) 0.77
Molecular biology of melanoma. J Am Acad Dermatol (2012) 0.76
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature (2012) 2.35
Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron (2002) 2.08
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov (2012) 1.97
Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc Natl Acad Sci U S A (2013) 1.77
Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci (2002) 1.63
Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer (2006) 1.60
Morphological and physiological features of a set of spinal substantia gelatinosa neurons defined by green fluorescent protein expression. J Neurosci (2004) 1.55
Optogenetic stimulation of MCH neurons increases sleep. J Neurosci (2013) 1.53
Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res (2010) 1.50
LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res (2008) 1.42
Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J (2012) 1.35
Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol (2005) 1.34
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A (2002) 1.30
Mechanisms of neuropeptide Y, peptide YY, and pancreatic polypeptide inhibition of identified green fluorescent protein-expressing GABA neurons in the hypothalamic neuroendocrine arcuate nucleus. J Neurosci (2005) 1.30
Neuropeptide Y inhibits hypocretin/orexin neurons by multiple presynaptic and postsynaptic mechanisms: tonic depression of the hypothalamic arousal system. J Neurosci (2004) 1.26
Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J Virol (2009) 1.25
Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J Virol (2006) 1.24
Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases. Am J Surg Pathol (2004) 1.23
Prefrontal cortex-projecting glutamatergic thalamic paraventricular nucleus-excited by hypocretin: a feedforward circuit that may enhance cognitive arousal. J Neurophysiol (2006) 1.22
Gonadotropin inhibitory hormone inhibits basal forebrain vGluT2-gonadotropin-releasing hormone neurons via a direct postsynaptic mechanism. J Physiol (2009) 1.22
Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci (2008) 1.21
Kisspeptin directly excites anorexigenic proopiomelanocortin neurons but inhibits orexigenic neuropeptide Y cells by an indirect synaptic mechanism. J Neurosci (2010) 1.20
Direct and indirect inhibition by catecholamines of hypocretin/orexin neurons. J Neurosci (2005) 1.18
Differential target-dependent actions of coexpressed inhibitory dynorphin and excitatory hypocretin/orexin neuropeptides. J Neurosci (2006) 1.14
Refuting the challenges of the developmental shift of polarity of GABA actions: GABA more exciting than ever! Front Cell Neurosci (2012) 1.12
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest (2013) 1.12
Agouti-related peptide and MC3/4 receptor agonists both inhibit excitatory hypothalamic ventromedial nucleus neurons. J Neurosci (2008) 1.11
Hypocretin/orexin innervation and excitation of identified septohippocampal cholinergic neurons. J Neurosci (2004) 1.09
Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis. Am J Pathol (2009) 1.07
Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proc Natl Acad Sci U S A (2007) 1.07
Colonic ganglioneuromatous polyposis and metastatic adenocarcinoma in the setting of Cowden syndrome: a case report and literature review. Hum Pathol (2011) 1.06
Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice. J Neurosci (2011) 1.05
Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma. Proc Natl Acad Sci U S A (2013) 1.04
Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol (2011) 1.04
Nicotine excites hypothalamic arcuate anorexigenic proopiomelanocortin neurons and orexigenic neuropeptide Y neurons: similarities and differences. J Neurophysiol (2011) 1.03
Utility of MMP-1, p53, E-cadherin, and collagen IV immunohistochemical stains in the differential diagnosis of adenomas with misplaced epithelium versus adenomas with invasive adenocarcinoma. Am J Surg Pathol (2002) 1.02
Mu-opioid receptor-mediated depression of the hypothalamic hypocretin/orexin arousal system. J Neurosci (2008) 1.01
Hypocretin increases impulse flow in the septohippocampal GABAergic pathway: implications for arousal via a mechanism of hippocampal disinhibition. J Neurosci (2002) 0.99
Rapid direct excitation and long-lasting enhancement of NMDA response by group I metabotropic glutamate receptor activation of hypothalamic melanin-concentrating hormone neurons. J Neurosci (2007) 0.99
Neuroendocrine proopiomelanocortin neurons are excited by hypocretin/orexin. J Neurosci (2009) 0.98
Peptide YY(3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J Neurosci (2005) 0.97
Melanin-concentrating hormone depresses L-, N-, and P/Q-type voltage-dependent calcium channels in rat lateral hypothalamic neurons. J Physiol (2002) 0.96
piggyBac transposon somatic mutagenesis with an activated reporter and tracker (PB-SMART) for genetic screens in mice. PLoS One (2011) 0.95
Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal. J Neurosci (2007) 0.94
Direct excitation of hypocretin/orexin cells by extracellular ATP at P2X receptors. J Neurophysiol (2005) 0.93
Hypocretin-2 (orexin-B) modulation of superficial dorsal horn activity in rat. J Physiol (2002) 0.92
Direct inhibition of arcuate proopiomelanocortin neurons: a potential mechanism for the orexigenic actions of dynorphin. J Physiol (2013) 0.92
Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice. Cancer Res (2007) 0.90
GABA excitation in mouse hilar neuropeptide Y neurons. J Physiol (2007) 0.90
Differential distribution of hypocretin (orexin) and melanin-concentrating hormone in the goldfish brain. J Comp Neurol (2005) 0.90
Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging. Mol Imaging Biol (2013) 0.90
Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol Cell Biol (2005) 0.90
Mitochondrial DNA depletion analysis by pseudogene ratioing. J Neurosci Methods (2005) 0.89
Vasopressin increases locomotion through a V1a receptor in orexin/hypocretin neurons: implications for water homeostasis. J Neurosci (2008) 0.89
Precancer in mice: animal models used to understand, prevent, and treat human precancers. Toxicol Pathol (2006) 0.88
CD4+ T-cell reconstitution reduces cytomegalovirus in the immunocompromised brain. J Virol (2005) 0.88
Viral mutagenesis as a means for generating novel proteins. J Virol (2009) 0.88
Neurons synthesizing melanin-concentrating hormone identified by selective reporter gene expression after transfection in vitro: transmitter responses. J Neurophysiol (2003) 0.87
Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity. J Virol (2012) 0.85
Perifollicular fibroma in Birt-Hogg-Dubé syndrome: an association revisited. J Cutan Pathol (2012) 0.84
Investigative pathology: leading the post-genomic revolution. Lab Invest (2011) 0.83
Cannabinoids excite circadian clock neurons. J Neurosci (2010) 0.81
Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain. J Virol (2009) 0.81
Thyrotropin-releasing hormone (TRH) inhibits melanin-concentrating hormone neurons: implications for TRH-mediated anorexic and arousal actions. J Neurosci (2012) 0.81
Reversed synaptic effects of hypocretin and NPY mediated by excitatory GABA-dependent synaptic activity in developing MCH neurons. J Neurophysiol (2012) 0.81
Enhanced excitatory input to melanin concentrating hormone neurons during developmental period of high food intake is mediated by GABA. J Neurosci (2009) 0.80
Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells. J Virol (2014) 0.79
A new mechanism of release from senescence: suppression of p16INK4a by beta-catenin. Pigment Cell Melanoma Res (2008) 0.79
Developing neurons make the switch. Nat Neurosci (2004) 0.78
LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells. J Virol (2012) 0.77
Vasopressin and oxytocin excite MCH neurons, but not other lateral hypothalamic GABA neurons. Am J Physiol Regul Integr Comp Physiol (2012) 0.76
Bystander attenuation of neuronal and astrocyte intercellular communication by murine cytomegalovirus infection of glia. J Virol (2007) 0.76
Mouse models of human cancers (part 3). Comp Med (2004) 0.76
Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas. Melanoma Res (2017) 0.75
Melanotic schwannoma arising in association with nevus of Ota: 2 cases suggesting a shared mechanism. Am J Dermatopathol (2009) 0.75
Autoimmune acrosyringitis with ductal cysts: reclassification of case of eruptive syringoma. J Cutan Pathol (2009) 0.75
Short circuiting the circadian clock. Nat Neurosci (2002) 0.75
A transient epidermolysis bullosa simplex-like phenotype associated with bexarotene treatment in a G138E KRT5 heterozygote. J Cutan Pathol (2010) 0.75